Sabin’s Ebola Sudan vaccine was found to be immunogenic and safe based on previous clinical trials. Credit: Sabin Vaccine Institute.

The Biomedical Advanced Research and Development Authority (BARDA) has awarded a multi-year contract to the Sabin Vaccine Institute for developing and producing single-dose vaccine candidates for Ebola Sudan and Marburg virus diseases.

BARDA, part of the Administration for Strategic Preparedness and Response (ASPR) of the US Department of Health and Human Services, will initially invest around $35m for the production of up to 100,000 doses of the Ebola Sudan virus (ChAd3-SUDV) vaccine.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The funding will expand to up to $214m for advancing the vaccine candidates’ development and production for Ebola Sudan and Marburg viruses. Currently, there are no licensed vaccines against these viruses.

Sabin stated that the ChAd3-SUDV vaccine was the first to arrive in the Republic of Uganda during the recent Ebola Sudan virus outbreak.

Sabin chief executive officer Amy Finan said: “Sabin successfully delivered Ebola Sudan vaccine doses to Uganda within 79 days of the start of the outbreak – quite an impressive accomplishment.

“This new contract enables Sabin to produce up to 100,000 doses, so the world is prepared in advance for future outbreaks.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The organisation has commenced Phase II clinical trial planning in Uganda and Kenya. 

Sabin’s Ebola Sudan vaccine was found to be immunogenic and safe based on previous clinical trials.

The vaccine has also shown quick protection, efficacy and durability of up to 12 months in nonhuman primate studies.

Additionally, the BARDA contract includes support to produce Sabin’s Marburg virus (ChAd3-MARV) vaccine.

The BARDA Administration for Strategic Preparedness and Response and the Department of Health and Human Services are funding the project.